

**Havrix™ 1440 Adult / 720 Junior**  
**Inactivated hepatitis A vaccine**

**QUALITATIVE AND QUANTITATIVE COMPOSITION**

Suspension for injection.

One dose (1.0 ml) of Havrix 1440 Adult contains :

Hepatitis A virus (inactivated) <sup>1,2</sup>	1440 ELISA Units
<sup>1</sup> Produced on human diploid (MRC-5) cells	
<sup>2</sup> Adsorbed on aluminium hydroxide, hydrated	0.50 milligrams Al <sup>3+</sup>

One dose (0.5 ml) of Havrix 720 Junior contains

Hepatitis A virus (inactivated) <sup>1,2</sup>	720 ELISA Units
<sup>1</sup> Produced on human diploid (MRC-5) cells	
<sup>2</sup> Adsorbed on aluminium hydroxide, hydrated	0.25 milligrams Al <sup>3+</sup>

Turbid liquid suspension. Upon storage, a fine white deposit with a clear colourless supernatant can be observed.

**PHARMACEUTICAL FORM**

Suspension for injection.

**CLINICAL PARTICULARS**

**Indications**

**Havrix™** is indicated for active immunisation against hepatitis A virus (HAV) infection in subjects at risk of exposure to HAV.

**Havrix™** will not prevent hepatitis infection caused by other agents such as hepatitis B virus, hepatitis C virus, hepatitis E virus or other pathogens known to infect the liver.

In areas of low to intermediate prevalence of hepatitis A, immunisation with **Havrix™** is particularly recommended in subjects who are, or will be, at increased risk of infection such as:

Travellers. Persons travelling to areas where the prevalence of hepatitis A is high.

These areas include Africa, Asia, the Mediterranean basin, the Middle East, Central and South America.

Armed Forces. Armed Forces personnel who travel to higher endemicity areas or to areas where hygiene is poor have an increased risk of HAV infection. Active immunisation is indicated for these individuals.

Persons for whom hepatitis A is an occupational hazard or for whom there is an increased risk of transmission. These include employees in day-care centres, nursing, medical and paramedical personnel in hospitals and institutions, especially

gastroenterology and paediatric units, sewage workers, food handlers, among others.

Persons at increased risk due to their sexual behaviour. Homosexuals, persons with multiple sexual partners.

Haemophiliacs.

Abusers of Injectable Drugs.

Contacts of Infected Persons. Since virus shedding of infected persons may occur for a prolonged period, active immunisation of close contacts is recommended.

Persons who require protection as part of hepatitis A outbreak control or because of regionally elevated morbidity.

Specific population groups known to have a higher incidence of hepatitis A.

For example American Indians, Eskimos, recognised community-wide HAV epidemics.

Subjects with chronic liver disease or who are at risk of developing chronic liver disease ( e.g. Hepatitis B (HB) and Hepatitis C (HC) chronic carriers and alcohol abusers).

In areas of intermediate to high prevalence of hepatitis A (eg Africa, Asia, the Mediterranean basin, the Middle East, Central and South America) susceptible individuals should be considered for active immunisation. These include children and adolescents especially in high socio-economic groups and urban areas.

## Dosage and Administration

- **Posology**

### **Primary vaccination**

- Adults from age 19 years and onwards

A single dose of **Havrix™ 1440 Adult** (1.0 ml suspension) is used for primary immunisation.

- Children and adolescents from 1 year up to and including 18 years of age

A single dose of **Havrix™ 720 Junior** (0.5 ml suspension) is used for primary immunisation.

### **Booster vaccination**

After primary vaccination with either **Havrix™ 1440 Adult** or **Havrix™ 720 Junior**, a booster dose is recommended at any time between 6 and 12 months after the primary dose in order to ensure long term protection.

### Method of administration

**Havrix™** is for intramuscular administration. The vaccine should be injected in the deltoid region in adults and children, in the antero-lateral part of the thigh in young children.

The vaccine should not be administered in the gluteal region.

The vaccine should not be administered subcutaneously/intradermally since administration by these routes may result in a less than optimal anti-HAV antibody response.

**Havrix™ should under no circumstances be administered intravascularly.**

**Havrix™** should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects. Firm pressure should be applied to the injection site (without rubbing) for at least two minutes.

## **Contraindications**

**Havrix™** should not be administered to subjects with known hypersensitivity to any component of the vaccine (see *Qualitative and quantitative composition* and *List of excipients*), or to subjects having shown signs of hypersensitivity after previous administration of **Havrix™**.

## **Warnings and Precautions**

As with other vaccines, the administration of **Havrix™** should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection, however, is not a contra-indication for vaccination.

It is possible that subjects may be in the incubation period of a hepatitis A infection at the time of vaccination. It is not known whether **Havrix™** will prevent hepatitis A in such cases.

In haemodialysis patients and in subjects with an impaired immune system, adequate anti-HAV antibody titres may not be obtained after a single dose of **Havrix™** and such patients may therefore require administration of additional doses of vaccine.

**Havrix™** contains traces of neomycin. The vaccine should be used with caution in patients with known hypersensitivity to this antibiotic.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available for treatment in case of a rare anaphylactic event following the administration of the vaccine.

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

**Havrix™** can be given to HIV-infected persons.

Seropositivity against hepatitis A is not a contra-indication.

## **Interactions**

Since **Havrix™** is an inactivated vaccine its concomitant use with other inactivated vaccines is unlikely to result in interference with the immune responses.

Concomitant administration of typhoid, yellow fever, cholera (injectable) or tetanus does not interfere with **Havrix™** immune response.

Concomitant administration of immunoglobulines does not impact the protective effect of the vaccine.

When concomitant administration of other vaccines or of immunoglobulins is considered necessary, the products must be given with different syringes and needles and at different injection sites.

## **Pregnancy and Lactation**

### **Pregnancy**

Adequate human data on use during pregnancy and adequate animal reproduction studies are not available. However, as with all inactivated viral vaccines the risks to the foetus are considered to be negligible. **Havrix™** should be used during pregnancy only when clearly needed.

## **Lactation**

Adequate human data on use during lactation and adequate animal reproduction studies are not available. Although the risk can be considered as negligible, **Havrix™** should be used during lactation only when clearly needed.

## **Effects on Ability to Drive and Use Machines**

The vaccine is unlikely to produce an effect on the ability to drive and use machines.

## **Adverse Reactions**

- **Clinical trial data**

The safety profile presented below is based on data from more than 5300 subjects. Frequencies per dose are defined as follows:

Very common: ≥ 10%

Common: ≥ 1% and < 10%

Uncommon: ≥ 0.1% and < 1%

Rare: ≥ 0.01% and < 0.1%

Very rare: < 0.01%

### **Infections and infestations**

Uncommon: upper respiratory tract infection, rhinitis

### **Metabolism and nutrition disorders**

Common: appetite lost

### **Psychiatric disorders:**

Very common: irritability

### **Nervous system disorders**

Very common: headache

Common: drowsiness

Uncommon: dizziness

Rare: hypoesthesia, paraesthesia

### **Gastrointestinal disorders**

Common: gastrointestinal symptoms (such as diarrhoea, nausea, vomiting)

### **Skin and subcutaneous tissue disorders**

Uncommon: rash

Rare: pruritus

### **Musculoskeletal and connective tissue disorders**

Uncommon: myalgia, musculoskeletal stiffness

### **General disorders and administration site conditions**

Very common: pain and redness at the injection site, fatigue

Common: swelling, malaise, fever ( $\geq 37.5^{\circ}\text{C}$ ), injection site reaction (such as induration)

Uncommon: influenza like illness

Rare: chills

- **Post-marketing data**

### **Immune system disorders**

Anaphylaxis, allergic reactions including anaphylactoid reactions and mimicking serum sickness

Nervous system disorders

Convulsions

Vascular disorders

Vasculitis

Skin and subcutaneous tissue disorders

Angioneurotic oedema, urticaria, erythema multiforme

Musculoskeletal and connective tissue disorders

Arthralgia

## Overdose

Cases of overdose have been reported during post-marketing surveillance. Adverse events reported following overdosage were similar to those reported with normal vaccine administration.

## PHARMACOLOGICAL PROPERTIES

### Pharmacodynamics

Pharmaco-therapeutic group: Hepatitis A vaccines, ATC code J07BC02.

**Havrix™** protects against hepatitis A by inducing specific anti-HAV antibodies.

In clinical studies involving subjects of 16-50 years of age, specific humoral antibodies against HAV were detected in more than 88% of vaccinees at day 15 and 99 % at month 1 following administration of a single dose of **Havrix™ 1440 Adult**.

In clinical studies involving subjects of 1-18 years of age, specific humoral antibodies against HAV were detected in more than 93% of vaccinees at day 15 and 99 % of vaccinees one month following administration of **Havrix™ 720 Junior**.

In a study designed to interrupt an epidemic of hepatitis A in Alaska, nearly 5,000 persons were vaccinated with one dose of **Havrix™ (1440 Adult or 720 Junior according to the age of the vaccinee)**. 92% of tested recipients developed measurable anti-HAV responses. A vaccine coverage of 80% led to termination of the outbreaks.

Long term persistence of hepatitis A antibody titers following 2 doses of **Havrix™** given 6 to 12 months apart has been evaluated.

Data available after 17 years allows prediction that at least 95% and 90% of subjects will remain seropositive (>15 mIU/ml) 30 and 40 years after vaccination, respectively (see Table 1).

**Table 1: Predicted proportion with anti-HAV level ≥15 mIU/ml and 95% confidence intervals for studies HAV-112 and HAV-123.**

Year	≥15 mIU/ml	95% CI	
		LL	UL
<b>Predictions for HAV-112</b>			
25	97.69 %	94.22 %	100 %
30	96.53 %	92.49 %	99.42 %
35	94.22 %	89.02 %	98.93 %
40	92.49 %	86.11 %	97.84 %
<b>Predictions for HAV-123</b>			

<b>25</b>	97.22 %	93.52 %	100 %
<b>30</b>	95.37 %	88.89 %	99.07 %
<b>35</b>	92.59 %	86.09 %	97.22 %
<b>40</b>	90.74 %	82.38 %	95.37 %

Current data do not support the need for booster vaccination among immunocompetent subjects after a 2 dose vaccination course.

## **Pharmacokinetics**

Evaluation of pharmacokinetic properties is not required for vaccines.

## **Clinical Studies**

See section “*Pharmacodynamics*”

## **Pre-clinical Safety Data**

Appropriate safety tests have been performed.

In an experiment in 8 non-human primates, the animals were exposed to an heterologous hepatitis A strain and vaccinated 2 days after exposure. This post exposure vaccination resulted in protection of all animals.

## **PHARMACEUTICAL PARTICULARS**

### **List of Excipients**

Aluminium hydroxide, amino acids for injections, disodium phosphate, monopotassium phosphate, polysorbate 20, potassium chloride, sodium chloride, water for injections.

### **Incompatibilities**

**Havrix™** should not be mixed with other vaccines or immunoglobulins in the same syringe.

### **Shelf Life**

The expiry date of the vaccine is indicated on the label and packaging.

### **Special Precautions for Storage**

**Havrix™** should be stored at +2°C to +8°C.

**Do not freeze;** discard if vaccine has been frozen.

Additional information on the stability:

The following experimental data give an indication of the stability of the vaccine and are not recommendations for storage: the monodose of **Havrix™** has been kept at +37°C for 3 weeks without a significant loss of potency.

## **Nature and Contents of Container**

**Havrix™** is presented in a glass vial or prefilled glass syringe.  
The vials and syringes are made of neutral glass type I, which conforms to European Pharmacopoeia Requirements.

## **Instructions for Use/Handling**

The vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. Before use of **Havrix™**, the vial/syringe should be well shaken to obtain a slightly opaque white suspension. Discard the vaccine if the content appears otherwise.

For further information, please contact manufacturer.

Not all presentations are available in every country.

**Havrix is a trademark of the GlaxoSmithKline group of companies.**

Version number: GDS011/IPI07/ Date of issue: 26/Mar/2012

Manufacturer: GlaxoSmithKline Biologicals s.a. Rue de l'Institut 89, B-1330 Rixensart, Belgium